2. (Amended) The method according to claim 1, which is intended to reactivate the expression of at least one foetal gene in adult tissues such as to restore the presence and/or the localization of at least one foetal protein.

3. (Amended) The method according to claim 1, wherein the foetal gene codes for the embryonic form of the protein encoded by the deficient gene.

4. (Amended) The method according to claim 1, wherein the compound able to induce NO formation is L-arginine, or one of its derivatives, forming a substrate for NO-synthase or promoting availability of the substrate.

A'

5. (Amended) The method according to claim 1, wherein the definite gene is the dystrophin gene and the foetal gene is the utrophin gene.

6. (Amended) The method according to claim 1, wherein the deficient gene is the haemoglobin gene and the foetal gene is the foetal haemoglobin gene.

7. (Amended) The method according to claim 1, wherein the disease resulting from the deficiency of an adult gene is a muscular dystrophy, thalassaemia or sickle-cell disease.

A1

8. (Amended) Pharmaceutical composition comprising NO and/or at least one NO donor or a compound able to release, promote or induce NO formation in cells, associated in said composition with a pharmaceutically acceptable vehicle.

A2

--9. The method according to claim 7, wherein the muscular dystrophy is Duchenne or Becker muscular dystrophy. --